A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer Full Text
Clinical Cancer Research, 05/04/2012
Chi KN et al. – Figitumumab is biologically active in prostate cancer. PSA declines in treatment naive patients were observed, potentially mediated by insulin–like growth factor 1 receptor (IGF–IR) effects on androgen receptor expression. These results support the clinical relevance of IGF–IR signalling in prostate cancer and justify further clinical trials.